Emcure Pharmaceuticals Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Emcure Pharmaceuticals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹1,008
Per ShareLot Size
14 Shares
Minimum Investment
₹14,112
Issue Size
₹1,952.03 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Emcure Pharmaceuticals Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
54.42%
Issue Type
Book Building
ISIN
INE168P01015
About the Company
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. The company is a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, it is present across acute and chronic therapeutic areas, and its key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.
Industry Overview
The global pharmaceutical market is expected to sustain growth at a compound annual growth rate of approximately 5.0% to 5.5% between the calendar years 2023 and 2028, to reach approximately US$1,900 billion (approximately Rs.157 trillion) to US$1,950 billion (approximately Rs.161 trillion) in the calendar year 2028. The Indian domestic formulations segment (consumption) is expected to grow at a CAGR of approximately 8% to 9% between the Financial Years 2024 and 2029, to reach approximately Rs.2.9 trillion to Rs.3.0 trillion in the Financial Year 2029, aided by strong demand from the rising incidence of chronic diseases, increased awareness and access to quality healthcare.
Company History
Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. The Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of the Company and the certificate of incorporation of the Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, the Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of the Company was changed to `Emcure Pharmaceuticals Limited', pursuant to its Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.
Products & Services
- Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
Growth Strategy
- Increase its Market Share in the Domestic Market.
- Continue to Invest in Research & Development and Manufacturing Capabilities to Enhance and Grow our Differentiated Product Portfolio.
- Deepen and Expand its International Presence with a Focused Go-to-Market Approach.
- Pursue Strategic Acquisitions, Partnerships and In-Licensing Arrangements.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 19,375,070 equity shares of face value of Rs. 10 each ("Equity Shares") of Emcure Pharmaceuticals Limited (The "Company") for cash at a price of Rs. 1,008^ per equity share (including a share premium of Rs. 998 per equity share) (the "Offer Price") aggregating to Rs. 1952.03^ crores (the "Offer") comprising a fresh issue of 7,946,231 equity shares of face value of Rs. 10 each aggregating to Rs. 800.00^ crores by the company (the "Fresh Issue") and an offer for sale of 11,428,839 equity shares of face value of Rs. 10 each aggregating to Rs. 1152.03 crores including 420,000 equity shares of face value of Rs. 10 each aggregating to Rs. 42.34 crores by Satish Ramanlal Mehta, 1,268,600 equity shares of face value of Rs. 10 each aggregating to Rs. 127.88 crores by Namita Vikas Thapar, 10,000 equity shares of face value of Rs. 10 each aggregating to Rs. 1.01 crores by Samit Satish Mehta and 40,000 equity shares of face value of Rs. 10 each aggregating to Rs. 4.03 crores by Sunil Rajanikant Mehta (the "Promoter Selling Shareholders"), 7,234,085 equity shares of face value of Rs. 10 each aggregating to Rs. 729.20 crores by BC Investments iv limited (the "Investor Selling Shareholder"), 1,342,586 equity shares of face value of Rs. 10 each aggregating to Rs. 135.33 crores by the promoter group selling shareholders as set out under annexure a (the "Promoter Group Selling Shareholders"), 300,000 equity shares of face value of Rs. 10 each aggregating to Rs. 30.24 crores by Arunkumar Purshotamlal Khanna (the "Individual Selling Shareholder"), and 813,568 equity shares of face value of Rs. 10 each aggregating to Rs. 82.01 crores by other selling shareholders as set out under annexure a (the "Other Selling Shareholders", and collectively with the promoter selling shareholders, promoter group selling shareholders, individual selling shareholder and the investor selling shareholder, the "Selling Shareholders", and each individually, as a "Selling Shareholder" and such offer for sale of equity shares of face value of Rs. 10 each by the selling shareholders, the "Offer for sale"). The offer included a reservation of 108,900 equity shares of face value of Rs. 10 each, aggregating to Rs. 10.00 crores^, for subscription by eligible employees (constituting up to 0.06% of the post-offer paid-up equity share capital)(the "Employee Reservation Portion"). The company, in consultation with the book running lead managers, offered a discount of 8.93% to the offer price (equivalent to Rs. 90 per equity share) to eligible employees biddng under the employee reservation portion ("Employee Discount"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer constituted 10.25% and 10.19%, respectively, of the post-offer paid-up equity share capital of the company. Tthe face value of the equity share is Rs. 10 each and the offer price is 100.80 times the face value of equity shares. ^A discount of Rs. 90 per equity share was offered to eligible employees bidding in the employee reservation portion.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Well-placed to leverage leading position in the domestic market.
- Demonstrated capabilities of building brands.
- Large, diversified and fast-growing product portfolio in international markets.
- Strong R&D capabilities driving differentiated portfolio of products.
- Extensive and diversified manufacturing capacity.
- Any manufacturing or quality control problems may damage its reputation, subject it to regulatory action, and expose it to litigation or other liabilities, which could adversely affect the company reputation, business, financial condition and results of operations.
- Its failures to comply with applicable quality standards may result in product liability claims, which could adversely affect its business, financial condition, cash flows and results of operations.
- Its manufacturing and research and development operations are subject to operational risks. Any slowdown or shutdown in its manufacturing or research and development operations could adversely affect its business, financial condition and results of operations.
- The company is subject to extensive government regulations and if its fail to obtain, maintain or renew the company statutory and regulatory licenses, permits and approvals required to operate its business, the company's business, financial condition, results of operations and cash flows may be adversely affected.
- Any disruptions to the supply, or increases in the pricing, of the raw materials and finished products that its outsource, may adversely affect the supply and pricing of its products and, in turn, adversely affect the company's business, cash flows, financial condition and results of operations.